中枢神经系统自身免疫性疾病的治疗性免疫耐受性 - - 前景,挑战和陷
Andreas Lutterotti1, Roland Martin2
1Cellerys AG, Wagistrasse 21, Schlieren 8952, Switzerland; Center for Multiple Sclerosis and Clinical Neuroimmunology, Bellevue Medical Group and Department of Neurology, Clinic Hirslanden, Zurich, Switzerland.
抗原特异性免疫耐受性为治疗诸如多发性硬化症 (MS) 等中枢神经系统 (CNS) 自免疫性疾病提供了一个有希望的方法. 这一策略旨在选择性地使有害的免疫反应沉默,保持整体免疫功能,以获得更安全,持续的缓解.
科学领域:
- 神经免疫学 神经免疫学
- 自免疫性疾病 自免疫性疾病
- 中枢神经系统 (CNS) 疾病
背景情况:
- 自免疫性中枢神经系统疾病 (MS,NMOSD,MOGAD) 涉及自反应性免疫反应引起的慢性炎症.
- 目前的免疫疗法可能会导致广泛的免疫抑制,从而损害基本的免疫功能.
- 抗原特异性免疫耐受性提供了一个更安全的替代方案,只针对病原体反应.
研究的目的:
- 探索针对中枢神经系统自身免疫性疾病的基于抗原的耐受性策略.
- 审查了解病理生理学和目标抗原的进展.
- 确定临床翻译的挑战和未来方向.
主要方法:
- 审查目前对中枢神经系统自身免疫病理生理学的理解.
- 对针对T和B细胞反应的基于抗原的耐受性策略的分析.
- 对MS和NMOSD临床试验数据和挑战的评估.
主要成果:
- 了解疾病机制的进步使得基于抗原的耐受性发展成为可能.
- 临床试验强调了抗原选择,管理和试验设计方面的挑战.
- 描述表位和开发耐受性生物标志物对于未来的进步至关重要.
结论:
- 抗原特异性免疫耐受性有可能在治疗中枢神经系统自身免疫性方面带来范式转变.
- 这种方法承诺疾病特异性,安全和持续的缓解,而无需普遍免疫抑制.
- 对表位和生物标志物的进一步研究对于成功的临床应用至关重要.
更多相关视频
08:47Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
Published on: May 8, 2016
08:17Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024
相关概念视频
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
01:25What is a Nervous System?
01:14The Parasympathetic Nervous System
01:25The Sympathetic Nervous System
01:38What is the Immune System?
01:25The Central Dogma